I think that for various reasons unknown but highly debated, the current SP does not reflect company performance - when the SP and company performance are more closely aligned the number of theories on the HC threads will decrease and the SP will hopefully stabilise and 'make more sense' to the myriad of small or should I say non-institutional investors here on HC. Swami Roate obviously has good connections in the US and Asia, and from what I understand his connections in India are outstanding, see his LinkedIn profile where he states:
While with J&J, I also had the opportunity to lead several high-impact, international community programs. Of these, I’m most proud of the Neonatal Resuscitation Program in India that I co-founded with the Indian Academy of Pediatrics and the Government of India. This program grew to become the single-largest child survival project in the country by training over 200K midwives and primary healthcare workers and helped reduce the country’s infant mortality rate by 30% in five years.
You cannot achieve this without high level government connections - just not possible. This is what is exciting about the ROW sales, they have the potential, even though profit margins will be much smaller, sales may be high, and remember the old chestnut, "a small percentage of a large number is still a large number". I vacillated previously about selling when the SP was near $4, but as we remember that was when blue sky potential was built into the SP and the SP was driven up artificially only to be shorted heavily at the highest price. As a LTH I too would prefer the SP to be closer to $3 than where it currently sits, but I am powerless to change some things - the SP being one of them. I would like to re-evaluate my thoughts and position in the company towards the EOFY 2023, when things may have picked up from here, we shall see, stay well and lets keep the debates and opinions insightful and respectful, even though we may not agree with them!
(20min delay)